Does Fatty15 Lower Cholesterol? Here’s What the Research Says
Because C15 (the fatty acid in Fatty15) is a saturated fat, people are often surprised that it’s studied for favorable cardiometabolic markers rather than harmful ones. Research has linked higher C15 levels to lower type 2 diabetes risk in many cohorts, but results for heart disease and lipids are mixed, Fatty15 is not a cholesterol medication, and the evidence is associative and early [10][11][12]. Here’s the balanced answer.
The Odd-Chain Saturated Fat Distinction
Not all saturated fats behave the same. C15 is an odd-chain saturated fatty acid, and odd-chain saturated fats (found in dairy) have been associated in observational research with lower type 2 diabetes risk, whereas the more common even-chain saturated fats such as palmitic acid were linked to higher risk, and results for cardiovascular outcomes are inconsistent [4][10][6]. This is a key reason C15 is studied differently from typical “bad” saturated fat.
Research note: In mice, a gut-bacteria-made pentadecanoic acid reduced atherosclerotic plaque by around 50% and appeared to work by inhibiting HMG-CoA reductase (the statin target); pentadecanoic acid was also depleted in people with dyslipidaemia. A mouse study published in Nature, not a human trial [14].
What Research Shows on C15 and Lipids
- Mixed associations [10][11][12]: higher circulating C15 has been linked to lower type 2 diabetes risk in observational studies, but not consistently to cardiovascular outcomes, and in a 24-week dairy trial in adults with diabetes a rise in pentadecanoic acid went with higher total cholesterol, VLDL cholesterol and triglycerides [10][11][12].
- Preclinical support: mechanistic work suggests C15 influences metabolic pathways relevant to lipid handling.
- One randomized trial did find an LDL effect: in the TANGO trial, 88 women with fatty liver disease followed a Mediterranean-style diet for 12 weeks with or without C15. Both diet groups improved their total cholesterol and triglycerides, and the group taking C15 lowered LDL cholesterol further than diet alone[1]. That is a real randomized finding, and it is also one secondary outcome, in one 12-week trial, in one population, on top of a diet that was itself doing most of the work. It has not been replicated.
- Still not a cholesterol treatment: no trial has tested C15 on its own against a cholesterol-lowering drug, or measured whether it changes heart attacks or strokes.
The cholesterol evidence for C15 points in different directions
Tended to lower non-HDL
Purified C15:0 raised plasma levels and tended to lower non-HDL cholesterol and triglycerides without raising LDL-C. Described in a review.
Rise went with higher lipids
When C15:0 rose on high-fat dairy, it went with higher total cholesterol, VLDL-C and triglycerides.
Plaque down around 50%
A gut-bacteria-made odd-chain fatty acid cut atherosclerotic plaque in a mouse model. Not a human trial.
No firm human evidence says a C15 supplement lowers cholesterol.
Three different designs: a small randomized trial, a diet trial ancillary analysis, and a mouse study. Source: World Journal of Cardiology 2025; Nutrients 2021; Nature 2026.
Chart: c15hub.com: The cholesterol evidence for C15 points in different directions
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
Does That Mean Fatty15 Lowers Cholesterol?
Not in the way a statin or proven cholesterol therapy does. The honest reading is that C15 is associated with lower diabetes risk but not consistently with healthier lipid markers or heart outcomes, and [10][11][12] you should not take Fatty15 as a cholesterol-lowering drug or expect it to replace one. If you have high cholesterol, work with your clinician on proven management.
A Reasonable Way to Think About It
C15 is better described as an under-studied nutrient with a diabetes-risk association and one LDL signal in a diet trial than as a supportive nutrient for cardiometabolic health or a cholesterol treatment [10][1][11]. If that research interests you, you can get the molecule affordably through a generic C15 supplement, and our Fatty15 review covers whether the branded version is worth the premium.
What Large Studies Say About Odd-Chain Fats and Cardiometabolic Risk
The idea that C15 might be a “good” saturated fat rests mostly on cohort data. A 2022 meta-analysis in Frontiers in Nutrition pooled 49 prospective studies of circulating saturated fatty acids. Higher total saturated fatty acid levels were associated with higher risk of cardiovascular disease (a 50 percent increase), coronary heart disease (63 percent) and stroke (38 percent), and even-chain saturated fats such as palmitic acid tracked with higher risk too. Odd-chain saturated fats, including C15 and C17, went the other way, with relative risks between 0.62 and 0.91. The authors still concluded that their findings support current advice to reduce saturated fat intake as part of healthy dietary patterns, and called for more work on the odd-chain results.
That nuance matters. C15 is a trace component of the saturated fat in dairy, so the finding is not permission to eat more saturated fat. If anything, it suggests that something about the odd-chain fraction, or about what it stands in for, differs from the rest.
The strongest consistent signal is for type 2 diabetes rather than for cholesterol itself. The EPIC-InterAct case-cohort study, published in The Lancet Diabetes and Endocrinology in 2014, found that plasma phospholipid C15 was inversely associated with incident type 2 diabetes (hazard ratio 0.79 per standard deviation), while palmitic acid was positively associated (1.26). A 2018 pooled analysis in PLOS Medicine of 16 cohorts, with 63,682 participants and 15,180 diabetes cases, reported a hazard ratio of 0.80 for C15 across its 10th to 90th percentile range. Neither paper measures LDL cholesterol, so they speak to the cardiometabolic picture, not to a lipid panel.
The heart-disease picture is weaker. In CARDIA and ARIC, plasma C15 was not associated with incident cardiovascular disease, and Mendelian randomization found no evidence that C15 causally affects blood pressure, heart rate or hypertension. The authors concluded the evidence is not consistent with a causal cardiovascular benefit of C15, a supplement they note is marketed as heart-healthy. A narrative review also reports null findings in UK Biobank and the Danish Diet, Cancer and Health Study, and a possible U-shaped pattern at very high levels [11][13].
Why a Blood Level Is Not the Same as a Dose
A 2017 review in Current Opinion in Lipidology (on milk fat biomarkers) explains that C15 in blood mostly reflects dairy fat intake, and it concludes that the biomarker results for cardiovascular outcomes are inconsistent and that odd-chain biomarkers are overall not linked to cardiovascular disease risk, while the link to lower diabetes risk is more consistent. It also warns that residual confounding should be considered until interventional data and mechanisms are available. A 2016 review in Advances in Nutrition (Pfeuffer and Jaudszus) adds that C15 can also be made in the body, for example from gut-derived propionic acid.
So a high C15 level in a cohort might come from eating dairy, from gut biology, or from the overall pattern of someone who eats well, and each of those could carry its own risk profile. Swallowing 100 mg of purified C15 is a different intervention from any of them, which is why intervention trials matter more than associations for this question.
Dairy Is Not One Food, and Cholesterol Shows It
If C15 were the whole story behind dairy and heart health, all dairy foods would behave alike. They do not. A 2015 systematic review and meta-analysis in Nutrition Reviews pooled five randomized trials comparing hard cheese with butter at similar polyunsaturated-to-saturated fat ratios. At about 145 grams of cheese a day, LDL cholesterol was 6.5 percent lower than on butter (a difference of 0.22 millimoles per liter), though HDL cholesterol was also 3.9 percent lower. The authors said it was unclear whether calcium, particular saturated fatty acids or the food matrix explained the difference. The takeaway is that the effect of a dairy food on blood lipids depends on much more than its C15 content, so cohort associations between “dairy biomarkers” and health cannot be translated directly into a capsule’s effect.
The TANGO Trial in More Detail
The one randomized trial with an LDL result is TANGO (Chooi et al., American Journal of Clinical Nutrition, 2024). It randomized 88 Chinese women with nonalcoholic fatty liver disease to one of three arms for 12 weeks: a Mediterranean-like Asian diet plus C15 (31 women), the same diet without C15 (28), or their habitual diet (29). Weight loss in the three groups was 4.0, 3.4 and 1.5 kilograms respectively, and liver fat fell by 33, 30 and 10 percent. Both diet groups improved total cholesterol, triglycerides and a liver enzyme (gamma-glutamyl transferase) more than the control group. The abstract then states that C15 supplementation reduced LDL cholesterol further and increased the abundance of Bifidobacterium adolescentis. It does not report how large the extra LDL reduction was or the supplement dose, so look at the full text before quoting a number.
Three limitations apply. The participants were all women with fatty liver in one Chinese setting, the trial ran 12 weeks, and the C15 arm was layered on a diet change that did most of the lipid work. The LDL finding is therefore one result worth replicating, not a general claim that C15 lowers LDL in everyone.
The Benchmark Set by Cholesterol Drugs
For perspective on what “proven” means in this field, consider statins. A 2015 Lancet meta-analysis from the Cholesterol Treatment Trialists’ Collaboration combined individual data from 174,149 participants in 27 randomized trials. LDL fell by roughly 1.1 millimoles per liter in statin-versus-control trials, and each 1.0 millimole per liter reduction was associated with a rate ratio for major vascular events of 0.78 in men and 0.84 in women, with reduced all-cause mortality. Those are hard clinical events in very large trials. No trial of C15 has measured heart attacks, strokes or death, and the one LDL result comes from 88 women. That gap in evidence is the reason Fatty15 should not be treated as a replacement for any prescribed cholesterol treatment.
What the Brand Claims
Fatty15’s FAQ states that studies showed daily pentadecanoic acid supported healthy glucose and cholesterol levels, along with liver and red blood cell function, “in relevant models,” and that population studies link C15 to better metabolic and heart health. It also argues that dairy fat carries larger amounts of other saturated fats, such as C16, that are associated with negative effects. Those are brand statements; the 2020 Scientific Reports paper behind them (Venn-Watson, Lumpkin and Dennis) reports in vivo effects on dyslipidemia, among other things, and itself says further studies are needed.
Using This Information Sensibly
If you are managing cholesterol, the useful framing is that C15 is an under-studied nutrient with one encouraging LDL signal, not a lipid therapy. If you decide to try it alongside your clinician’s plan, a repeat lipid panel after about 12 weeks, the length of the trial, gives you a personal data point, though it cannot separate the capsule from diet, weight or seasonal changes.
Frequently Asked Questions
Does Fatty15 lower cholesterol?
One 12-week randomized trial did find that adding C15 to a Mediterranean-style diet lowered LDL cholesterol further than the diet alone[1], so the effect is not purely associational any more. It remains a single unreplicated secondary outcome, and no trial has tested C15 against a cholesterol medication or measured cardiovascular events. Treat it as a supportive nutrient, not a cholesterol treatment.
Is C15 a good or bad saturated fat?
C15 is an odd-chain saturated fat, which research associates with lower type 2 diabetes risk, while results for heart disease are inconsistent, one reason [10][4] it’s studied so differently.
Can Fatty15 replace my cholesterol medication?
No. If you’re prescribed cholesterol medication, keep taking it and consult your clinician. Fatty15 is not a proven substitute.
Does Fatty15 raise cholesterol?
No trial has shown that C15 raises cholesterol, but the evidence is thin: in a 24-week trial of daily high-fat dairy in adults with diabetes, a rise in pentadecanoic acid was tied to higher total cholesterol, VLDL cholesterol and triglycerides, though that was dairy, not a capsule. A review of the 200 mg capsule trial describes a tendency toward lower non-HDL cholesterol and triglycerides without raising LDL [12][13].
Did any trial find that C15 lowers LDL cholesterol?
One did. In the 2024 TANGO trial of 88 women with fatty liver disease, adding C15 to a Mediterranean-style diet for 12 weeks reduced LDL cholesterol further than the diet alone. The abstract does not give the size of that reduction, and it has not been replicated.
Do odd-chain saturated fats lower the risk of heart disease?
Cohort data associate higher odd-chain levels with lower cardiometabolic risk, but a 2017 review says biomarker results for cardiovascular outcomes are inconsistent and that the diabetes association is the more consistent one. These are observational studies and cannot show that the fat itself is protective.
Is cheese better for LDL than butter?
In a 2015 meta-analysis of five randomized trials, hard cheese produced lower LDL cholesterol than butter, though it also lowered HDL. It shows dairy foods differ from one another, not that C15 explains the difference.
References
- Chooi YC, Zhang QA, Magkos F, et al. Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. American Journal of Clinical Nutrition. 2024;119(3):788-799. PMID 38035997
- Venn-Watson S, Lumpkin R, Dennis EA. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential? Scientific Reports. 2020;10:8161. PMID 32424181
- Li Z et al. Saturated fatty acid biomarkers and risk of cardiometabolic diseases: A meta-analysis of prospective studies. Frontiers in nutrition (2022). PMID 36046138
- Forouhi NG et al. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. The lancet. Diabetes & endocrinology (2014). PMID 25107467
- Imamura F et al. Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. PLoS medicine (2018). PMID 30303968
- Risérus U et al. Milk fat biomarkers and cardiometabolic disease. Current opinion in lipidology (2017). PMID 27906713
- Pfeuffer M et al. Pentadecanoic and Heptadecanoic Acids: Multifaceted Odd-Chain Fatty Acids. Advances in nutrition (Bethesda, Md.) (2016). PMID 27422507
- de Goede J et al. Effect of cheese consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials. Nutrition reviews (2015). PMID 26011901
- Cholesterol Treatment Trialists’ (CTT) Collaboration et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (London, England) (2015). PMID 25579834
- Sellem L et al. Can individual fatty acids be used as functional biomarkers of dairy fat consumption in relation to cardiometabolic health? A narrative review. The British journal of nutrition (2022). PMID 35086579
- Brian T. Steffen et al. Plasma pentadecanoic acid is modestly related to cardiovascular health in CARDIA and ARIC cohorts: observational associations without evidence of causality. Frontiers in Nutrition (2026). PMID 41743064
- Mitri J et al. Plasma Free Fatty Acids and Metabolic Effect in Type 2 Diabetes, an Ancillary Study from a Randomized Clinical Trial. Nutrients (2021). PMID 33807135
- Mercola J Pentadecanoic acid (C15:0) and cardiovascular disease: A narrative review. World journal of cardiology (2025). PMID 41480001
- Yin C et al. A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice. Nature (2026). PMID 42844473
Related: Does Fatty15 Help With Fatty Liver? · Does Fatty15 Work? · Fatty15 Review
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.